Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.
A Nature Chemical Biology paper published May 2026 reported TerminaTOR, a genetically encoded peptide inhibitor of mTORC1 that can be targeted to specific subcellular locations and used to dissect mTORC1 biology in living cells. Targeted to the lysosome, TerminaTOR inhibits canonical lysosomal mTORC1 and induces autophagy — recapitulating rapamycin's pharmacology. Targeted to the nucleus, TerminaTOR specifically inhibits nuclear mTORC1 and reveals a previously uncharacterized regulatory function: nuclear mTORC1 controls transcription of CCAAT-motif-containing genes and promotes cancer cell proliferation. The work creates a tool for spatially separating canonical (cytoplasmic) and noncanonical (nuclear) mTORC1 functions and identifies nuclear mTORC1 as a potentially druggable axis distinct from the lysosomal pathway. Therapeutic implication: cancer programs targeting mTORC1 might benefit from nucleus-selective inhibitors that spare lysosomal autophagy.
A Nature Communications paper published May 13, 2026 reported that chiral engineering of tripeptide-drug conjugates (PDCs) — systematically varying the L/D amino-acid configuration in the peptide moiety — controls phase behavior between liquid-liquid phase separation (LLPS) and β-sheet-rich hydrogel formation. PDCs with alternating L/D residues underwent LLPS in solution; all-L or all-D PDCs formed structured hydrogels. The chirality-controlled phase behavior is a design lever for PDC drug-product engineering: LLPS-prone conjugates dissolve readily for parenteral dosing, while hydrogel-forming variants enable sustained-release depots or injection-site retention. The work expands the design space for peptide-drug conjugate formulation, joining the broader May 2026 PDC research cycle alongside the Avacta AVA6103 FOCUS-01 trial start and the Bicycle Therapeutics ASCO Duravelo-2 readout.
Beijing Frontier Research Center for Biological Structure (FRCBS) at Tsinghua University organized an international Peptide Design Competition this year with about 300 participants from around the world designing peptide candidates targeting NK2R — a G-protein-coupled receptor involved in energy metabolism and appetite regulation. The competition is structured as a benchmarking exercise to test how well AI-driven structural predictions hold up under experimental scrutiny, with participants submitting designs that are then synthesized and tested for binding and functional activity. NK2R is a target of growing interest in the obesity-pharmacology field as the GLP-1 receptor space saturates and pharmaceutical R&D groups look for the next-generation metabolic-disease receptor that could complement GLP-1/GIP/glucagon agonism. The framework — AI design followed by wet-lab validation — is positioned as a community blueprint for de novo peptide discovery at large.
A 2026 Pharmaceuticals (MDPI) comment paper responds to the Józwiak et al. 2025 multifunctionality review of BPC-157, focusing on the peptide's role in targeting angiogenesis and modulating nitric oxide's cytotoxic versus protective actions. The response paper argues BPC-157's clinical claim breadth — wound healing, GI ulcer repair, tendon healing, neuroprotection — derives from a single biochemical hub: the peptide's interaction with vascular endothelial growth factor receptor 2 (VEGFR2) signaling and the NO/cGMP axis. The discussion lands as BPC-157 sits on the FDA's bulks-list review track for the July 23-24 PCAC meeting, with the underlying mechanistic literature still anchored on a small number of research groups. The Pharmaceuticals exchange illustrates the pre-clinical evidence gap that PCAC will weigh against the wide compounding-pharmacy demand signal.
A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.
A Chemical Communications (Royal Society of Chemistry) 2026 review on peptide-based drug design using generative AI synthesizes the methods landscape behind the wave of community competitions and pharmaceutical-industry de novo programs that landed in 2026. The review covers ProteoGPT and related protein-language-model architectures, AlphaFold3-based pose prediction, diffusion-model peptide structure generation, and the experimental-validation cycle that turns AI designs into bench-tested candidates. It frames the Tsinghua FRCBS NK2R Peptide Design Competition and the published ultra-long-acting GLP-1 receptor agonist de novo design work as proof-points that the AI-design stack has crossed the threshold from generative novelty to drug-discovery utility. The piece lands as the AI/peptide field tracks toward routine kilogram-scale syntheses (enlicitide PCSK9, others) and into Phase 1/2 candidates inside roughly 18 months from in silico design.
A Nature Biotechnology paper from a multi-institution collaboration introduced deep peptide recognition profiling (PRP) — a yeast-display platform integrated with protein-language models that maps T-cell receptor binding across the proteome for individual TCRs. Applied to HLA-B*27:05-restricted TCRs from patients with ankylosing spondylitis and acute anterior uveitis, the platform identified hundreds to over 6,000 unique peptide ligands per TCR and surfaced candidate autoantigens. Predicted binding scores correlated significantly with experimental T-cell activation across multiple TCRs. The model outperformed AlphaFold3 and tFold-TCR in predicting T-cell activation — meaningful for autoimmune-disease antigen discovery and personalized neoantigen cancer-vaccine design alike. The mechanistic implication: the CDR3β loop arches over the center of the HLA-B27-bound peptide and accounts for most contacts, with CDR3α positioned peripherally.
A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.
April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.
A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.
A 2026 Science Advances paper demonstrated that systematically changing the orientation and placement of a single cancer-targeting peptide within a vaccine construct leads to formulations that significantly enhance immune response. One specific vaccine design consistently outperformed others by shrinking tumors, extending animal survival, and generating larger numbers of highly active cancer-killing T-cells. The work is mechanistically important for the broader personalized neoantigen vaccine pipeline (Mount Sinai PGV001, BioNTech autogene cevumeran, Evaxion EVX-01) because peptide-orientation engineering has been an under-systematized variable in current vaccine designs. The findings provide a generalizable engineering principle that could inform second-generation neoantigen vaccine constructs heading into late 2026 and 2027.
A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.
The EASO 2026 Nature Medicine framework published May 14, presented at ECO 2026 — formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications with differentiated complication-specific recommendations — has generated initial reception coverage. The Endocrine Society and American Diabetes Association haven't yet issued formal endorsement or counter-response statements as of May 16, though informal commentary from US endocrinologists has been broadly favorable. The framework's main US-specific gap is its silence on cost and insurance access — the algorithm assumes prescribers can choose between semaglutide and tirzepatide based on clinical indication, but US patients without diabetes face the Medicare Part D weight-loss-only exclusion. The Medicare GLP-1 Bridge launching July 1, 2026 partly addresses that gap; broader integration awaits CMS rulemaking. ADA 2026 Scientific Sessions in New Orleans June 5-8 will be the next inflection point for guideline alignment between US and EASO positions.
The Lancet's 'Making Treatment for Obesity More Equitable' editorial (March 2026) and an accompanying medRxiv preprint (Hill et al., March 4, 2026) synthesized 2024-2025 active pharmaceutical ingredient shipment data to estimate generic semaglutide production costs at $28-140/person-year for injectable formulations and $186-380/person-year for oral formulations. By the end of 2026, generic injectable semaglutide could be available in 160 countries covering 69% of global T2DM and 84% of clinical obesity. The 10 countries where Novo Nordisk's 2026 patents expired represent 44% of the global population and 48% of the global obesity burden — including Brazil, Canada, China, India, and Turkey. The constraint isn't manufacturing economics; it's device-patent thickets (57% of analyzed semaglutide patents are device patents) and policy coordination (pooled procurement, voluntary licensing, tiered pricing).
The European Association for the Study of Obesity published an updated pharmacological framework in Nature Medicine, presented at ECO 2026 in Istanbul on Thursday May 14. Semaglutide and tirzepatide are recommended as first-line treatment for obesity across most complications. Tirzepatide is preferred for obstructive sleep apnea and MASH; semaglutide is preferred for knee osteoarthritis and established cardiovascular disease — and is the only agent with current evidence supporting MASH-fibrosis improvement. The framework integrated evidence through November 21, 2025 from 62 randomized controlled trials. The algorithm uses obesity-related complication presence as the primary treatment-selection factor and provides the first major obesity-society guideline to formally privilege incretin-based therapy across the indication mix.
A second body-composition substudy from REDEFINE 1 presented May 14 at ECO 2026 broke out the DXA subgroup by treatment arm. At week 68, CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) produced -23.9% weight reduction in the DXA subgroup, compared with -16.6% on semaglutide 2.4 mg alone, -15.0% on cagrilintide 2.4 mg alone, and -2.8% on placebo. The fat-mass-to-lean-tissue ratios were favorable across all active arms: 66.9% fat-mass contribution on CagriSema, 69.7% on semaglutide, 62.9% on cagrilintide. The cagrilintide monotherapy arm is the first head-to-head body-composition signal for amylin-only therapy at clinically meaningful weight-loss levels — relevant to Zealand and Roche's petrelintide Phase 3 program and the broader amylin-versus-incretin debate.
Sarfaraz K. Niazi at the University of Illinois Chicago College of Pharmacy published a March 20, 2026 review in Frontiers in Drug Delivery arguing oral peptide delivery success depends fundamentally on molecular pharmacology rather than formulation technology. The thesis: semaglutide's approval represents a rare boundary case enabled by its ~168-hour half-life and time-integrated pharmacodynamics, not a generalizable breakthrough. The author proposes a negative-selection framework identifying which peptides should be excluded from oral development — short elimination half-lives, dose sensitivity, regulatory variability constraints — and routes excluded candidates toward pulmonary, nasal, or long-acting injectable alternatives. The framework matters for the next-generation pipeline beyond Foundayo and Wegovy pill: many programs currently chasing oral delivery may be better served by alternative routes.